DOP2006000016A - 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2. - Google Patents
2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.Info
- Publication number
- DOP2006000016A DOP2006000016A DO2006000016A DO2006000016A DOP2006000016A DO P2006000016 A DOP2006000016 A DO P2006000016A DO 2006000016 A DO2006000016 A DO 2006000016A DO 2006000016 A DO2006000016 A DO 2006000016A DO P2006000016 A DOP2006000016 A DO P2006000016A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- pharmaceutically acceptable
- diseases
- xvi
- formula
- accompanied
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a un compuesto de la formula (XVI) en la que R, R2, R3, R4, R5, R6, R7 y n son como se definen aqui, o una de sus sales, hidratos o solvatos farmacéuticamente aceptables, uno de sus profármacos farmacéuticamente aceptables, o una sal, hidrato o solvato del profármaco fannacéuticamente aceptable, una composición farmaceutica que comprende una cantidad terapéuticamente eficaz de uno o mas compuestos segun la fórmula (XVI) en mezcla con un vehiculo farmacéuticamente aceptable, un método para tratar a un paciente que sufre un trastorno mediado por la PGD2 incluyendo, pero sin limitarse a ellas, enfermedades alérgicas (tales como rinitis albrgica, conjuntivitis alérgica, dermatitis atópica, asma bronquial y alergia a los alimentos), mastocitosis sistémica, trastornos acompaflados de la activación sistémica de los mastocitos, shock anafildctico, broncoconstricción, bronquitis, urticaria, eczema, enfermedades acompafladas de prurito (tales como dermatitis atópica y urticaria), enfermedades (tales como cataratas, desprendimiento de retina, inflamación, infección y trastornos del sueflo) que se generan de forma secundaria como resultado de la conducta acompafiadas de prurito (tales como escarificaciones y contusiones), inflamación, enfermedades pulmonares obstructivas crónicas, lesiones por reperfusión isquémica, accidente cerebrovascular, artritis reumatoide crónica, pleuresia, colitis ulcerosa y similares, administrando a dicho paciente una cantidad terapeuticamente eficaz de un compuesto segun la formula (XVI).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64730705P | 2005-01-26 | 2005-01-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2006000016A true DOP2006000016A (es) | 2006-07-31 |
Family
ID=36282872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2006000016A DOP2006000016A (es) | 2005-01-26 | 2006-01-20 | 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20070265278A1 (es) |
| EP (1) | EP1844011A1 (es) |
| JP (1) | JP2008528606A (es) |
| KR (1) | KR20070110277A (es) |
| CN (1) | CN101146770A (es) |
| AR (1) | AR054726A1 (es) |
| AU (1) | AU2006209213A1 (es) |
| BR (1) | BRPI0607079A2 (es) |
| CA (1) | CA2595728A1 (es) |
| CR (1) | CR9214A (es) |
| DO (1) | DOP2006000016A (es) |
| GT (1) | GT200600030A (es) |
| IL (1) | IL184816A0 (es) |
| MA (1) | MA29259B1 (es) |
| MX (1) | MX2007008277A (es) |
| NO (1) | NO20074336L (es) |
| PA (1) | PA8661201A1 (es) |
| PE (1) | PE20060878A1 (es) |
| RU (1) | RU2007132166A (es) |
| SG (1) | SG158918A1 (es) |
| TN (1) | TNSN07251A1 (es) |
| TW (1) | TW200639151A (es) |
| UY (1) | UY29346A1 (es) |
| WO (1) | WO2006081343A1 (es) |
| ZA (1) | ZA200705449B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007276885A1 (en) * | 2006-07-25 | 2008-01-31 | Sanofi-Aventis | 2-phenyl-indoles as prostaglandin D2 receptor antagonists |
| MY147588A (en) | 2006-08-07 | 2012-12-31 | Actelion Pharmaceuticals Ltd | (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives |
| WO2008061006A1 (en) * | 2006-11-10 | 2008-05-22 | Wyeth | Substituted indan-2-yl, tetrahydronaphthalen-2-yl, or dihydr0-2h-chr0men-3-yl arylsulfonamides and methods of their use |
| US8362056B2 (en) * | 2007-11-05 | 2013-01-29 | Array Biopharma Inc. | 4-heteroaryl-substituted phenoxyphenylacetic acid derivatives |
| CA2790139C (en) | 2010-03-22 | 2018-03-13 | Actelion Pharmaceuticals Ltd | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators |
| US8722719B2 (en) * | 2010-10-06 | 2014-05-13 | Kureha Corporation | Amine compound and use for same |
| JP5964945B2 (ja) | 2011-04-14 | 2016-08-03 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | ７−（ヘテロアリ−ル−アミノ）−６，７，８，９−テトラヒドロピリド［１，２−ａ］インド−ル酢酸誘導体及びプロスタグランジンＤ２受容体調節剤としてのそれらの使用 |
| EP2548863A1 (en) * | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists. |
| EP2762141A4 (en) * | 2011-09-29 | 2015-03-25 | Shionogi & Co | THERAPEUTIC PHARMACEUTICAL PRODUCT AGAINST ALLERGIC RHINITIS COMPRISING A PGD2 ANTAGONIST AND A HISTAMINE ANTAGONIST |
| CN104011021B (zh) | 2011-12-21 | 2016-08-24 | 埃科特莱茵药品有限公司 | 杂环衍生物及其作为前列腺素d2受体调节剂的用途 |
| US9169270B2 (en) | 2012-07-05 | 2015-10-27 | Actelion Pharmaceuticals Ltd. | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators |
| WO2014066568A1 (en) | 2012-10-24 | 2014-05-01 | Winthrop-University Hospital | Non-invasive biomarker to identify subjects at risk of preterm delivery |
| JP6168520B2 (ja) * | 2013-09-17 | 2017-07-26 | 国立大学法人 千葉大学 | インドール化合物、ｄｐプロスタノイド受容体アンタゴニスト、それを用いた薬剤、及びｄｐプロスタノイド受容体アンタゴニストの使用。 |
| JP2015089886A (ja) * | 2013-11-06 | 2015-05-11 | 国立大学法人名古屋大学 | 嵩高い置換基を有する化合物を用いた植物成長調整剤 |
| CA2939892C (en) | 2014-03-17 | 2020-03-31 | Idorsia Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| CN106103437A (zh) | 2014-03-18 | 2016-11-09 | 埃科特莱茵药品有限公司 | 氮杂吲哚乙酸衍生物及其作为前列腺素d2受体调节剂的用途 |
| CN108026093B (zh) | 2015-09-15 | 2021-11-16 | 爱杜西亚药品有限公司 | 结晶形式 |
| US20200264188A1 (en) | 2017-09-13 | 2020-08-20 | Progenity, Inc. | Preeclampsia biomarkers and related systems and methods |
| US12030879B2 (en) | 2018-03-02 | 2024-07-09 | Inflazome Limited | Sulfonyl acetamides as NLRP3 inhibitors |
| EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECLAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR TESTS |
| CN113173877B (zh) * | 2020-10-30 | 2023-10-27 | 江西师范大学 | 吲哚乙酰基亚氨基砜系列化合物及其制备方法 |
| CN115925606B (zh) * | 2023-01-05 | 2023-10-13 | 宁夏医科大学 | 一种5-（3-（磺酰胺基）苯基）-1h-吡咯-2-羧酸衍生物及其制备方法和应用 |
| EP4691466A1 (en) | 2023-07-25 | 2026-02-11 | The Eye Hospital of Wenzhou Medical University | Use of ptgds inhibitor in preparation of drug for treating cataracts |
| CN117599052A (zh) * | 2023-07-25 | 2024-02-27 | 温州医科大学附属眼视光医院 | Ptgds的抑制剂在制备治疗白内障药物上的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5496844A (en) * | 1992-05-08 | 1996-03-05 | Otsuka Pharmaceutical Factory, Inc. | Indole derivatives |
| FR2751966B1 (fr) * | 1996-08-01 | 1998-10-30 | Union Pharma Scient Appl | Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique |
| US6500853B1 (en) * | 1998-02-28 | 2002-12-31 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| DE10204462A1 (de) * | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
| JP2004024655A (ja) * | 2002-06-27 | 2004-01-29 | Aruze Corp | 遊技機 |
| JPWO2004078719A1 (ja) * | 2003-03-06 | 2006-06-08 | 小野薬品工業株式会社 | インドール誘導体化合物およびその化合物を有効成分とする薬剤 |
| SE0301569D0 (sv) * | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
| SE0303180D0 (sv) * | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| US7868037B2 (en) * | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| EP1771169A1 (en) * | 2004-07-14 | 2007-04-11 | PTC Therapeutics, Inc. | Methods for treating hepatitis c |
-
2006
- 2006-01-20 DO DO2006000016A patent/DOP2006000016A/es unknown
- 2006-01-24 PE PE2006000105A patent/PE20060878A1/es not_active Application Discontinuation
- 2006-01-25 SG SG201000540-3A patent/SG158918A1/en unknown
- 2006-01-25 KR KR1020077017292A patent/KR20070110277A/ko not_active Withdrawn
- 2006-01-25 EP EP06719551A patent/EP1844011A1/en not_active Withdrawn
- 2006-01-25 GT GT200600030A patent/GT200600030A/es unknown
- 2006-01-25 AR ARP060100278A patent/AR054726A1/es not_active Application Discontinuation
- 2006-01-25 WO PCT/US2006/002736 patent/WO2006081343A1/en not_active Ceased
- 2006-01-25 RU RU2007132166/04A patent/RU2007132166A/ru not_active Application Discontinuation
- 2006-01-25 CA CA002595728A patent/CA2595728A1/en not_active Abandoned
- 2006-01-25 JP JP2007553221A patent/JP2008528606A/ja active Pending
- 2006-01-25 BR BRPI0607079-5A patent/BRPI0607079A2/pt not_active IP Right Cessation
- 2006-01-25 AU AU2006209213A patent/AU2006209213A1/en not_active Abandoned
- 2006-01-25 CN CNA2006800097886A patent/CN101146770A/zh active Pending
- 2006-01-25 MX MX2007008277A patent/MX2007008277A/es not_active Application Discontinuation
- 2006-01-26 TW TW095102967A patent/TW200639151A/zh unknown
- 2006-01-26 PA PA20068661201A patent/PA8661201A1/es unknown
- 2006-01-26 UY UY29346A patent/UY29346A1/es unknown
-
2007
- 2007-06-28 CR CR9214A patent/CR9214A/es not_active Application Discontinuation
- 2007-07-03 TN TNP2007000251A patent/TNSN07251A1/en unknown
- 2007-07-04 ZA ZA200705449A patent/ZA200705449B/xx unknown
- 2007-07-24 IL IL184816A patent/IL184816A0/en unknown
- 2007-07-25 US US11/782,890 patent/US20070265278A1/en not_active Abandoned
- 2007-08-17 MA MA30150A patent/MA29259B1/fr unknown
- 2007-08-24 NO NO20074336A patent/NO20074336L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1844011A1 (en) | 2007-10-17 |
| UY29346A1 (es) | 2006-08-31 |
| IL184816A0 (en) | 2007-12-03 |
| TW200639151A (en) | 2006-11-16 |
| ZA200705449B (en) | 2009-01-28 |
| RU2007132166A (ru) | 2009-03-10 |
| MA29259B1 (fr) | 2008-02-01 |
| AR054726A1 (es) | 2007-07-11 |
| KR20070110277A (ko) | 2007-11-16 |
| TNSN07251A1 (en) | 2008-12-31 |
| WO2006081343A1 (en) | 2006-08-03 |
| JP2008528606A (ja) | 2008-07-31 |
| US20070265278A1 (en) | 2007-11-15 |
| AU2006209213A1 (en) | 2006-08-03 |
| PA8661201A1 (es) | 2006-09-08 |
| PE20060878A1 (es) | 2006-10-18 |
| MX2007008277A (es) | 2007-09-07 |
| GT200600030A (es) | 2006-09-27 |
| NO20074336L (no) | 2007-10-23 |
| CR9214A (es) | 2007-11-23 |
| CN101146770A (zh) | 2008-03-19 |
| BRPI0607079A2 (pt) | 2009-08-04 |
| SG158918A1 (en) | 2010-02-26 |
| CA2595728A1 (en) | 2006-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN07251A1 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
| ECSP088813A (es) | Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2 | |
| ECSP088362A (es) | Sal de dihidrógeno fosfato de un antagonista del receptor de prostaglandina d2 | |
| UA88485C2 (en) | 2,6-substituted-4-monosubstituted amino-pyrimidines as prostaglandin d2 receptor antagonists | |
| TNSN08515A1 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
| EA201691471A1 (ru) | Макроциклы с гетероциклическими группами p2' как ингибиторы фактора xia | |
| AR065622A1 (es) | Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona | |
| UY35972A (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| CO7160040A2 (es) | Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor activado de proteasa 4 (par4) para el tratamiento de agregación plaquetaria | |
| EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
| UY34960A (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| PE20151375A1 (es) | Compuestos ciclicos eter pirazol-4-il-heterociclil-carboxamida y metodos de utilizacion | |
| CO6460732A2 (es) | Antagonistas del receptor de cgrp | |
| UY33910A (es) | 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del SNC | |
| RU2018142605A (ru) | Селективный ингибитор фосфатидилинозитол-3-киназы-гамма | |
| JP2019505500A (ja) | 哺乳類ヒストンデアセチラーゼ活性の阻害剤として有用な二環式ヒドロキサム酸 | |
| MX2012007711A (es) | Compuestos de piruvamida como inhibidores de alergeno de peptidasa del grupo 1 de acaros del polvo. | |
| UA116480C2 (uk) | Похідна біфенілу та спосіб її одержання | |
| UA95303C2 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
| DOP2009000009A (es) | 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 | |
| CY1113582T1 (el) | 2,6-υποκατεστημενες-4-μονοϋποκατεστημενες amino-πυριμιδινες ως ανταγωνιστες υποδοχεων d2 των προσταγλανδινων | |
| DOP2015000029A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a |